SABCS 2021 | REACT: effect of celecoxib vs placebo as adjuvant therapy on DFS among patients with breast cancer

Charles Coombes, MD, PhD, Imperial College London, London, UK, provides an overview of the REACT study (NCT02429427), a randomized clinical trial evaluating the effect of celecoxib versus placebo as adjuvant therapy on disease-free survival among patients with breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.